effect overlay
activetrials
Movement Disorders

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy
 

HREC: 2020.317
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Non-Commercial
Movement Disorders

A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
 

HREC: 2023.188
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Commercial
Movement Disorders

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson's Disease
 

HREC: 2024.061
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Non-Commercial
Multiple Sclerosis

MS Immunity Project: The role of the peripheral immune system in various forms of Multiple Sclerosis (MS)
 

HREC: 2019.265
Principal Investigator: Dr Mastura Monif
Coordinator contact: Katherine Fazzolari
Funding: Non-Commercial
Multiple Sclerosis

Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study
 

HREC: 2019.340
Principal Investigator: Dr Mastura Monif
Coordinator contact: Katherine Fazzolari
Funding: Non-Commercial